Assembly Biosciences, Inc. $ASMB Shares Bought by Stempoint Capital LP

Stempoint Capital LP grew its holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) by 18.3% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 185,435 shares of the biopharmaceutical company’s stock after buying an additional 28,707 shares during the quarter. Stempoint Capital LP’s holdings in Assembly Biosciences were worth $5,146,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Informed Momentum Co LLC lifted its position in shares of Assembly Biosciences by 1.6% during the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after buying an additional 451 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in Assembly Biosciences by 4.2% in the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock worth $672,000 after acquiring an additional 800 shares in the last quarter. Geode Capital Management LLC increased its holdings in Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock worth $4,468,000 after acquiring an additional 1,212 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Assembly Biosciences by 4.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after acquiring an additional 1,634 shares during the period. Finally, Palumbo Wealth Management LLC raised its position in Assembly Biosciences by 7.2% during the fourth quarter. Palumbo Wealth Management LLC now owns 37,305 shares of the biopharmaceutical company’s stock worth $1,269,000 after acquiring an additional 2,507 shares during the period. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Trading Down 1.8%

ASMB opened at $25.11 on Thursday. Assembly Biosciences, Inc. has a twelve month low of $16.90 and a twelve month high of $39.71. The firm has a market capitalization of $399.00 million, a PE ratio of -228.25 and a beta of 1.08. The firm’s 50-day moving average price is $25.91 and its 200 day moving average price is $27.55.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The company had revenue of $8.21 million during the quarter, compared to the consensus estimate of $9.27 million. As a group, analysts predict that Assembly Biosciences, Inc. will post 1.9 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ASMB has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Monday, May 4th. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. Finally, Mizuho set a $45.00 price objective on Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Assembly Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

Assembly Biosciences Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.